Novo Nordisk strikes deal with Septerna to develop obesity pills

Taking stock of the drug industry, from the lab to the medicine chest

May 14, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Novo Nordisk STAT+ | Novo Nordisk strikes deal with Septerna to develop obesity pills The deal, worth up to $2.2 billion, broadens Novo's efforts to develop next-generation weight loss drugs, an area of tight competition. By Elaine Chen STAT+ | French trial sponsors are urged to bolster clinical trial transparency Only 57% of French clinical trial results were made public in registries maintained by the U.S. and EU between 2012 and 2022. By Ed Silverman Former FDA head Robert Califf says RFK Jr.'s vaccine rhetoric is 'doing harm' to Americans Ex-FDA chief Robert Califf says HHS Secretary Robert F. Kennedy Jr.'s vaccine stance is harming public health, warns of HHS chaos, politicization, staff exodus. By Lizzy Lawrence JUSTIN TALLIS/AFP via Getty Images STAT+ | GSK to buy experimental MASH drug for $1.2B upfront The deal for Boston Pharmaceuticals' efimosfermin will help the U.K. drugmaker shore up its pipeline of future medicines. By Andrew Joseph STAT+ | GOP embraces RFK Jr.'s MAHA at House hearing, but raises dissents from dental health to food dye reform GOP lawmakers tested the limits of how far they could push Kennedy without appearing to undermine him or his MAHA movement. By Lev Facher and Daniel Payne

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser